Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
Sign Up to like & getrecommendations! Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02397-21
Abstract: Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients… read more here.
Keywords: skin; omadacycline pharmacokinetics; comorbidities omadacycline; evaluation impact ... See more keywords